Clinical Trial: Early Postoperative Triple Targeted Therapy in Patients With CHD-PAH in the "Grey Zone"

U.S., Sept. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07844213) titled 'Early Postoperative Triple Targeted Therapy in Patients With CHD-PAH in the "Grey Zone"' on Aug. 30.

Brief Summary: The purpose of this study is to observe the efficacy of early application of triple targeted drug therapy, including trilostane, in patients with congenital heart disease who are in the "gray zone" of preoperative evaluation, have surgical repair indications after evaluation, and have undergone defect repair.

Study Start Date: Aug. 25, 2022

Study Type: INTERVENTIONAL

Condition: Congenital Heart Disease, Pulmonary Hypertension

Intervention: DRUG: Control group (ambrisentan plus tadalafil or macitentan plus tadala...